We have previously shown that tumor cellsgenetically modified to co-express IL-4 or IL-7 and B7.1have increased immunogenicity and provided vaccinessuperior to single gene transfectants or tumor cells/adjuvant mixture...We have previously shown that tumor cellsgenetically modified to co-express IL-4 or IL-7 and B7.1have increased immunogenicity and provided vaccinessuperior to single gene transfectants or tumor cells/adjuvant mixture.Tumor antigens can be presented eitherdirectly by tumor cells or be indirectly represented byhost APC(cross-priming).Here we asked whether B7.1and IL-7 or IL-4 improved in an additive fashion one pathway of antigen presentation or complemented each other by improving preferentially different pathways of antigen presentation.展开更多
文摘We have previously shown that tumor cellsgenetically modified to co-express IL-4 or IL-7 and B7.1have increased immunogenicity and provided vaccinessuperior to single gene transfectants or tumor cells/adjuvant mixture.Tumor antigens can be presented eitherdirectly by tumor cells or be indirectly represented byhost APC(cross-priming).Here we asked whether B7.1and IL-7 or IL-4 improved in an additive fashion one pathway of antigen presentation or complemented each other by improving preferentially different pathways of antigen presentation.
